Table 1.
Demographics, medical history, and travel information among confirmed monkeypox cases reported to GeoSentinel (May 1–July 1, 2022)
| Patients (n=226) | ||
|---|---|---|
| GeoSentinel site country | ||
| Spain | 79 (35%) | |
| Canada | 66 (29%) | |
| Germany | 16 (7%) | |
| France | 15 (7%) | |
| Belgium | 13 (6%) | |
| Netherlands | 8 (4%) | |
| Portugal | 7 (3%) | |
| Sweden | 6 (3%) | |
| Romania | 5 (2%) | |
| USA | 3 (1%) | |
| Israel | 2 (1%) | |
| South Africa | 2 (1%) | |
| UK | 2 (1%) | |
| Denmark | 1 (<1%) | |
| Argentina | 1 (<1%) | |
| Median age, years (range; IQR) | 37 (18–68; 32–43) | |
| Assigned male sex at birth | 226 (100%) | |
| History of smallpox vaccine | ||
| Yes | 16/182 (9%) | |
| No | 166/182 (91%) | |
| Immunocompromising conditions | ||
| Yes* | 96/209 (46%)† | |
| No | 113/209 (54%) | |
| HIV* | 92/209 (44%) | |
| CD4 T-cell count | ||
| Data available, n | 75 | |
| Median, cells per mm3 (range; IQR) | 713 (36–1659; 500–885) | |
| Undetectable HIV viral load | ||
| Yes | 76/83 (92%) | |
| No | 7/83 (8%) | |
| International travel during the 21 days before illness onset | ||
| Yes | 37/210 (18%) | |
| No | 173/210 (82%) | |
| Trip duration | ||
| Data available, n | 38 | |
| Median, days (range; IQR) | 5 (1–38; 4–9) | |
| Five most common travel destinations in previous 21 days before illness onset | ||
| Spain | 17/40 (43%) | |
| Portugal | 4/40 (10%) | |
| Belgium | 3/40 (8%) | |
| Italy | 3/40 (8%) | |
| Germany | 3/40 (8%) | |
| Reason for travel | ||
| Tourism | 32/36 (89%) | |
| Visiting friends or relatives | 4/36 (11%) | |
Data are n (%) or n/N (%), unless otherwise specified.
*
Not mutually exclusive.
†
Other immunocompromising conditions in addition to HIV included diabetes (n=6), and Crohn's disease (n=1).